One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL207280 Compound in Healthy Volunteers
Latest Information Update: 02 Dec 2021
At a glance
- Drugs CPL207-280CA (Primary) ; Metformin
- Indications Diabetic neuropathies; Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Celon Pharma
Most Recent Events
- 17 Aug 2021 Status changed from active, no longer recruiting to completed.
- 29 Jun 2021 Results (n=24) of part A portion of this dose-escalation study with single oral administration of CPL207280 in healthy subjects in fasting conditions presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 14 May 2021 Status changed from recruiting to active, no longer recruiting.